34 completed, 29 unknown, 15 recruiting, 6 not yet recruiting. 52 Phase 2, 22 Phase 1, 10 Not applicable, 9 Phase 3, 1 Early Phase 1.
Follow Advanced Gastric Cancer: new trials by email Literature Review of Advanced Gastric Cancer trials Research Report on Advanced Gastric Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project) Rilvegostomig, Pembrolizumab - Advanced Gastric Cancer | Phase 2 | Not yet recruiting | Vall d'Hebron Institute of Oncology | 50 | 2026-10-01 | 2026-08-26 |
| A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine - Esophageal Cancer, Advanced Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2026-09-04 | 2026-09-14 |
| Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma BHB810 - Gastric Cancer, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | BigHat Biosciences, Inc. | 164 | 2026-07-16 | 2026-10-20 |
| Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial Doxorubicin (Adriamycin), VRT106 - Advanced Gastric Cancer | Phase 2 | Not yet recruiting | Guangdong Provincial People's Hospital | 30 | 2026-03-01 | 2026-03-20 |
| A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer Trifluridine/Tipiracil (TAS-102) combined with Apatinib - Advanced Gastric Cancer | Not applicable | Not yet recruiting | Anhui Provincial Cancer Hospital | 30 | 2026-01-08 | 2026-01-28 |
| Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer Lucine-restricted diet - Advanced Gastric Cancer | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 73 | 2026-01-01 | 2026-04-17 |
| Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer XH001 Injection, Tumor vaccine-induced specific T-cell injection - Advanced Gastric Cancer | Phase 1 | Recruiting | Jia Wei | 18 | 2025-12-26 | 2026-02-25 |
| Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers Biological samples collection, questionnaires to collect patient reported outcomes - Advanced Breast Cancer, Advanced Gastric Cancer | Phase 2 | Recruiting | UNICANCER | 400 | 2025-11-14 | 2025-12-02 |
| Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Iparomlimab and Tuvonralimab (QL1706), SOX Chemotherapy - Gastric Cancer (GC), Gastroesophageal Junction Cancer | Phase 2 | Recruiting | Beijing Friendship Hospital | 32 | 2025-11-04 | 2026-01-06 |
| Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma SHR2554 Tablets, SHR-A1811 Injection, SHR-A1904 Injection - Advanced Gastric Cancer, Metastatic Gastric Cancer | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 351 | 2025-09-05 | 2025-09-10 |
| MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma Fruquintinib+Paclitaxel, Ramucirumab+Paclitaxel - Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Sun Yat-sen University | 1143 | 2025-09-05 | 2025-08-28 | |
| Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients Standardized Telenursing, Smart Cancer Care Plus - Early Gastric Cancer, Advanced Gastric Cancer | Not applicable | Recruiting | Ulsan University Hospital | 414 | 2025-07-09 | 2026-02-12 |
| Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer FAPI PET/CT Imaging, Grazytracer PET/CT Imaging - Advanced Gastric Cancer | Recruiting | Ruijin Hospital | 120 | 2025-06-17 | 2026-09-17 | |
| PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer SHR1701, SHR2554, CAPOX - Advanced Gastric Cancer, SHR1701 | Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 78 | 2025-06-15 | 2026-09-01 |
| HS-10502 Combination Treatment in Patients With Advanced Solid Tumors HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib - Recurrent Ovarian Cancer, HER2-negative | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 157 | 2025-05-07 | 2025-06-24 |
| SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT), Cadonilimab - Advanced Gastric Cancer, Advanced Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Zhang Tao | 26 | 2025-03-20 | 2025-04-27 |
| A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification BGB-53038, Tislelizumab, Cetuximab - Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer | Phase 1 | Terminated | BeOne Medicines | 47 | 2024-12-13 | 2026-07-08 |
| Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer Advanced Gastric Cancer | Recruiting | Yonsei University | 80 | 2024-12-01 | 2025-01-09 | |
| A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer Paclitaxel Polymeric Micelles for Injection combined with Fruquintinib Capsules - Advanced Gastric Cancer, Paclitaxel Polymeric Micelles for Injection | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 21 | 2024-12-01 | 2024-11-27 |
| A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer Advanced Gastric Cancer | Recruiting | Yonsei University | 300 | 2024-11-05 | 2025-01-09 |
Showing 20 of 92. Sign in to see all of them.
Stomach Neoplasms (23) · Breast Neoplasms (4) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Adenoma, Islet Cell (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Digestive System Neoplasms (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1)
Digestive System Diseases (26) · Neoplasms by Site (26) · Digestive System Neoplasms (25) · Gastrointestinal Diseases (25) · Neoplasms (25) · Gastrointestinal Neoplasms (24) · Stomach Diseases (22) · Breast Diseases (4) · Colonic Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Intestinal Diseases (4) · Intestinal Neoplasms (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4)
Capecitabine (10) · Paclitaxel (10) · apatinib (9) · Cisplatin (8) · Oxaliplatin (7) · Docetaxel (6) · Everolimus (5) · S 1 (combination) (5) · camrelizumab (5) · 130-nm albumin-bound paclitaxel (4) · Bevacizumab (3) · Drug Therapy (3) · Fluorouracil (3) · Irinotecan (3) · 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide (2)
Asan Medical Center (6) · Peking University (5) · Yonsei University (5) · Novartis Pharmaceuticals (4) · Samsung Medical Center (4) · Seoul National University Hospital (4) · Fujian Medical University (3) · Shanghai Zhongshan Hospital (3) · Fuda Cancer Hospital, Guangzhou (2) · Fudan University (2) · Krankenhaus Nordwest (2) · Pfizer (2) · Qilu Hospital of Shandong University (2) · AnewPharma (1) · Anhui Provincial Cancer Hospital (1)
China (42) · South Korea (31) · United States (11) · Germany (9) · Australia (6) · Japan (6) · Canada (5) · France (5) · Italy (5) · Spain (5) · Taiwan (4) · United Kingdom (4) · Belgium (3) · Israel (3) · Netherlands (3)
Yoon-Koo Kang, MD, PhD (4) · Do-Youn Oh, MD, PhD (2) · Lin Shen, MD (2) · Salah-Eddin Al-Batran, MD (2) · Aiping Zhou, MD (1) · Baek-Yeol Ryoo, MD,PhD (1) · Baorui Liu, MD, PHD (1) · Barbara Pistilli, MD, PhD (1) · Baruch Brenner, MD (1) · Chang Hak Sohn, M.D.PhD. (1) · Cheng Huang, MD (1) · Dae Young Zang, M.D.PhD (1)
PMID 11585919, PMID 18172173, PMID 18223320, PMID 18971936, PMID 19047087, PMID 20060288, PMID 20231677, PMID 20683045, PMID 21206985, PMID 21296855, PMID 21742485, PMID 23404155, PMID 23589827, PMID 23900716, PMID 23918952, PMID 23930209, PMID 24043745, PMID 25687867, PMID 26216386, PMID 26581547, PMID 27390847, PMID 30445943, PMID 30944763, PMID 32339253, PMID 32589866, PMID 33538338, PMID 33970027, PMID 34741530, PMID 36158692, PMID 37068504, PMID 37524953, PMID 38167806, PMID 38347177, PMID 38660276, PMID 38824242, PMID 42583940
2008 (1), 2009 (1), 2016 (1), 2023 (1)